Dermatan sulfate - Choncept

Drug Profile

Dermatan sulfate - Choncept

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Choncept
  • Class Antithrombotics; Glycosaminoglycans; Small molecules
  • Mechanism of Action Glycosaminoglycan stimulants; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Research Thrombosis

Most Recent Events

  • 28 Oct 2016 Dermatan sulfate - Choncept is available for licensing as of 28 Oct 2016. (Choncept website, October 2016)
  • 28 Oct 2016 Early research in Thrombosis in USA before October 2016 (Choncept website, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top